Something I keep noticing, and it bothered me more than usual this week, is how long a claim outlives the correction that should have killed it. We like to imagine science self-cleans, that a retraction lands and the record quietly resets. It doesn’t. A paper can be formally withdrawn and go right on being cited for years, by people who either never checked or did not want to. A study run in a few dozen mice can be more than a year old and still be dressed up as a promise about your bones. The claim has a longer life than the caveat, every time.
What stays with me is that this is not really a failure of information. The corrections exist. They are public, findable, sitting right there. What fails is attention, and the incentive to keep looking after the exciting version has already traveled. I find I trust the boring follow-up more than the first thrilling headline now, almost as a reflex. That reflex is most of the job.
So I read this week the way I hope you do: assuming the pretty number wants something from me, and asking who checked it after the applause died down.
Autoimmune & Inflammation
Oxford Found the Cells That May Mark Which Joints Rheumatoid Arthritis Attacks. They Were There Before You Were Born.
The joints rheumatoid arthritis attacks and the ones it spares are built differently in the womb, seeded with different cells before a single joint ever swells.
Investigations
The Zombie Papers: Retracted Stem-Cell Studies Still Feeding the Unproven-Cure Marketplace
A stem-cell paper retracted in November 2021 kept collecting citations for years, 72 by mid-2026, 27 of them after the notice went up, 15 since 2023 that never mention it. Two researchers counted, and named who is supposed to be cleaning up.
A Journal Built to Critique Capitalism Sold for €360,000. Its Fifteen Editors Read the New Fees and Quit.
A €360,000 sale, a €1,350 charge to publish, and a 25 percent fee to withdraw your own paper: the board of a journal built to critique capitalism read the new terms and resigned en masse.
Drugs & FDA
Sickle Cell Finally Has a Cure. It Costs $2.2 Million and Has Reached 64 People.
Casgevy has kept Victoria Gray crisis-free for seven years. Getting it still means wiping out a patient’s bone marrow with a chemo tied to infertility and malignancy warnings and paying about $3 million all in, and two years after approval only 64 people have been infused.
The ‘Bone-Building Switch’ Is Back in the Headlines. It Was Tested in Mice, and Only Mice
A publicly funded Leipzig compound rebuilt bone in ovariectomized mice, 8 per treated group. More than a year later the same experiment is still being sold to readers as a way to keep their bones strong for life.
Cancer
MD Anderson Made the Case for Radiation Cleanup After Immunotherapy. Then Its Own Trial Undercut It.
In the oligometastatic subgroup the strategy was built for, small and underpowered, the patients who added radiation trended the wrong way: median survival of 42 months against 75.8 for the drugs alone.
The Gene That Derails Brain Development Is Also a Brake on Your Killer T Cells
The same gene whose failure derails brain development in children sits like a brake on the CD8 T cells your body uses against chronic hepatitis B and cancer. Take the brake off in the lab, and their fate reroutes toward fighters that do not burn out.
Infectious Disease
The FDA Is Fighting a Flesh-Eating Parasite We Eradicated in 1966 With a Flea Pill From 2000
Nitenpyram was approved in 2000 to kill fleas. It is now the emergency tool against a parasite the United States wiped out in 1966, after the sterile-fly barrier that kept the screwworm out was breached in 2023.
A 2014 Trial Warned That Correcting Vaccine Fears Backfires on the Hesitant. Public Health Corrected Harder.
A randomized trial found that correcting MMR-autism fears left the most hesitant parents less likely to vaccinate. A decade later, a panel of credentialed doctors in Sydney shows the trust cost of correcting harder anyway.
Metabolic & Weight
Arsenic’s ‘Detox’ Pathway Has a Catch: The Workers Who Finished It Had Higher Blood Pressure
In 393 young Central American farmworkers carrying arsenic in their urine, the men whose bodies most efficiently converted it to DMA had systolic pressure up to 7 mmHg higher. The textbook calls that step detoxification.
Ozempic Gave Old Mice a Diet’s Longevity Payoff Without Slowing Their Metabolism
Semaglutide added 12 percent to old mice’s median lifespan and matched calorie restriction on aging measures without slowing their metabolism the way dieting does. It was also female mice only, three months of dosing, and zero human longevity data under the fountain-of-youth headlines.
Brain & Aging
Four Times the Odds of Losing Bowel Control: An ADHD Gut Signal Tangled Up With the Medication
Stimulants list constipation, nausea, and stomach pain among their common side effects. Most of the 23 studies pooling 1.9 million people never separated the medicated from the unmedicated, so the gut signal and the drug effect sit tangled together.
A Kinesiologist Argues Aging Has a Third Clock, and It Fades First
Georgia Southern’s Li Li argues aging has a third clock, movement span, that starts narrowing before any disease shows up. A compelling reframe with one catch: it’s an opinion paper carrying zero new data.
Nutrition & Food
Sprouts Have Poisoned Thousands for a Quarter Century. The Wellness World Still Eats Them Raw.
Salmonella from Idaho broccoli sprouts has sickened 22 across four states, one more entry in a tally that logged 53 sprout outbreaks in two decades. The raw-is-best dogma is what keeps them coming.
The Coffee-and-Bones Study Behind the Scary Headline Found No Significant Coffee Effect
The tea benefit was 0.003 grams per square centimeter, a number the authors themselves called too small to matter. The scary coffee result never cleared statistical significance.